Effects of electroacupuncture combined with paliperidone palmitate long-acting injection on withdrawal symptoms and neurotransmitters in methamphetamine addicts

被引:0
|
作者
Chen, Yu [1 ]
Wei, Wen-Jie [1 ]
Gong, Ji-Fen [1 ]
Qiao, Juan [1 ]
Wu, Chun-Xi [1 ]
Wang, Xiao-Jun [1 ]
Ding, Ying [1 ]
Chen, Hong-Yuan [1 ]
Lu, Hua-Xin [1 ]
Li, Ming-Chao [2 ]
Ji, Qiu-Ming [1 ]
机构
[1] Wuhan Wudong Hosp, Dept Psychiat, 46 Wudong St, Wuhan 430084, Peoples R China
[2] Wuhan Mental Hlth Ctr, Dept Psychiat, Wuhan, Peoples R China
关键词
Electroacupuncture treatment; methamphetamine; neurotransmitters; paliperidone palmitate long-acting injection; CLINICAL-PHARMACOLOGY; SCHIZOPHRENIA; NEUROTOXICITY;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
. Objective. To investigate the effects of electroacupuncture combined with paliperidone palmitate long-acting injection (PP-LAI) on withdrawal symptoms and neurotransmitters in methamphetamine (MA) addicts. Materials and methods. A total of 109 methamphetamine addicts, who were treated in the hospital from October 2021 to October 2022, were selected. According to the random number table, the patients were divided into the study group (n=54) and the control group (n=55), in which the control group was treated with PP-LAI and the study group was treated with electroacupuncture on the basis of the control group; the methamphetamine withdrawal symptom score scale was used to assess the therapeutic effect before treatment and within 12 months after treatment; the changes of brain neurotransmitters dopamine, gamma-aminobutyric acid, serotonin, acetylcholine values were compared between the two groups. Results .1) There was no statistical difference in MA withdrawal symptom scores between the two groups before treatment (p>0.05); 2) MA withdrawal symptom scores have a statistically significant difference between the study group and the control group after 3 and 6 months of treatment; 3) dopamine levels in the study group were significantly higher than those in the control group after 6 months of completion of treatment, and gamma-aminobutyric acid values and 5- serotonin values in the study group were significantly lower than those in the control group (p<0.05). Conclusions. Electroacupuncture combined with PP-LAI can partially improve the withdrawal symptoms and anxiety of methamphetamine addicts. This is a potential treatment for preventing relapse of withdrawal symptoms.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 50 条
  • [31] Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
    Mason, Katy
    Barnett, Joshua
    Pappa, Sofia
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2021, 11
  • [32] Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics
    Hargarter, Ludger
    Cherubin, Pierre
    Bergmans, Paul
    Keim, Sofia
    Rancans, Elmars
    Bez, Yasin
    Parellad, Eduard
    Carpiniello, Bernardo
    Vidailhet, Pierre
    Schreiner, Andreas
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2015, 58 : 1 - 7
  • [33] A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
    Nasrallah, Henry A.
    Gopal, Srihari
    Gassmann-Mayer, Cristiana
    Quiroz, Jorge A.
    Lim, Pilar
    Eerdekens, Marielle
    Yuen, Eric
    Hough, David
    NEUROPSYCHOPHARMACOLOGY, 2010, 35 (10) : 2072 - 2082
  • [34] A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia
    Henry A Nasrallah
    Srihari Gopal
    Cristiana Gassmann-Mayer
    Jorge A Quiroz
    Pilar Lim
    Mariëlle Eerdekens
    Eric Yuen
    David Hough
    Neuropsychopharmacology, 2010, 35 : 2072 - 2082
  • [35] A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
    Pandina, Gahan
    Lane, Rosanne
    Gopal, Srihari
    Gassmann-Mayer, Cristiana
    Hough, David
    Remmerie, Bart
    Simpson, George
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (01) : 218 - 226
  • [36] Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia
    Alphs, Larry
    Bossie, Cynthia A.
    Fu, Dong-Jing
    Ma, Yi-Wen
    Sliwa, Jennifer Kern
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1029 - 1042
  • [37] Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate
    Cordiner, Matthew
    Shajahan, Polash
    McAvoy, Sarah
    Bashir, Muhammad
    Taylor, Mark
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2016, 6 (01) : 22 - 32
  • [38] Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics
    Baser, Onur
    Xie, Lin
    Pesa, Jacqueline
    Durkin, Mike
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (05) : 357 - 365
  • [39] An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate
    Sliwa, Jennifer Kern
    Savitz, Adam
    Nuamah, Isaac
    Mathews, Maju
    Gopal, Srihari
    Elefant, Erica
    Najarian, Dean
    Alphs, Larry
    PERSPECTIVES IN PSYCHIATRIC CARE, 2018, 54 (04) : 530 - 538
  • [40] A change from risperidone long acting injection to paliperidone palmitate in an elderly patient - a cautionary tale
    Singh, Dhiren
    Williams, Owen
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2012, 46 (02) : 176 - 177